This content is restricted to subscribers
Continue Reading...
Did you know members enjoy unlimited free PDF downloads as part of their subscription? Subscribe today for instant access to this article and our entire library in your preferred format. Alternatively, you can purchase the PDF of this article individually.
Author Affiliations
- Centre for Addiction and Mental Health, Toronto, Ontario, Canada
- Department of Psychiatry, University of Toronto, Toronto, Ontario, Canada
- University Health Network, Toronto, Ontario, Canada
- Centre for Addiction and Mental Health, Toronto, Ontario, Canada
- Department of Psychiatry, University of Toronto, Toronto, Ontario, Canada
- Department of Psychiatry, Credit Valley Hospital, Mississauga, Ontario, Canada
- Chatham-Kent Clinical Trials Research Centre, Chatham, Ontario, Canada
- Centre for Addiction and Mental Health, Toronto, Ontario, Canada
- Centre for Addiction and Mental Health, Toronto, Ontario, Canada
- Department of Psychiatry, University of Toronto, Toronto, Ontario, Canada
- Corresponding author: Arun V. Ravindran, MD, 100 Stokes St, Toronto, ON M6J 1H4 Canada ([email protected]).
References (52)
- Mathers CBT, Ma Fat D. The Global Burden of Disease: 2004 Update. WHO website. https://apps.who.int/iris/bitstream/handle/10665/43942/9789241563710_eng.pdf. 2008.
- Whiteford HAP, Degenhardt L, Rehm J, et al. Global burden of disease attributable to mental and substance use disorders: findings from the Global Burden of Disease Study 2010. Lancet. 2013;382(9904):1575–1586. PubMed CrossRef
- Remes O, Brayne C, van der Linde R, et al. A systematic review of reviews on the prevalence of anxiety disorders in adult populations. Brain Behav. 2016;6(7):e00497. PubMed CrossRef
- Kessler RC, Sampson NA, Berglund P, et al. Anxious and non-anxious major depressive disorder in the World Health Organization World Mental Health Surveys. Epidemiol Psychiatr Sci. 2015;24(3):210–226. PubMed CrossRef
- Kessler RC, Berglund P, Demler O, et al; National Comorbidity Survey Replication. The epidemiology of major depressive disorder: results from the National Comorbidity Survey Replication (NCS-R). JAMA. 2003;289(23):3095–3105. PubMed CrossRef
- Bromet E, Andrade LH, Hwang I, et al. Cross-national epidemiology of DSM-IV major depressive episode. BMC Med. 2011;9(1):90. PubMed CrossRef
- Kessler RC, Chiu WT, Demler O, et al. Prevalence, severity, and comorbidity of 12-month DSM-IV disorders in the National Comorbidity Survey Replication. Arch Gen Psychiatry. 2005;62(6):617–627. PubMed CrossRef
- Gaspersz R, Nawijn L, Lamers F, et al. Patients with anxious depression: overview of prevalence, pathophysiology and impact on course and treatment outcome. Curr Opin Psychiatry. 2018;31(1):17–25. PubMed CrossRef
- May AM, Klonsky ED, Klein DN. Predicting future suicide attempts among depressed suicide ideators: a 10-year longitudinal study. J Psychiatr Res. 2012;46(7):946–952. PubMed CrossRef
- Sareen J, Cox BJ, Afifi TO, et al. Anxiety disorders and risk for suicidal ideation and suicide attempts: a population-based longitudinal study of adults. Arch Gen Psychiatry. 2005;62(11):1249–1257. PubMed CrossRef
- Belzer K, Schneier FR. Comorbidity of anxiety and depressive disorders: issues in conceptualization, assessment, and treatment. J Psychiatr Pract. 2004;10(5):296–306. PubMed CrossRef
- Kennedy SH, Lam RW, McIntyre RS, et al; CANMAT Depression Work Group. Canadian Network for Mood and Anxiety Treatments (CANMAT) 2016 clinical guidelines for the management of adults with major depressive disorder: section 3. Pharmacological treatments. Can J Psychiatry. 2016;61(9):540–560. PubMed CrossRef
- Spielmans GI, Berman MI, Linardatos E, et al. Adjunctive atypical antipsychotic treatment for major depressive disorder: a meta-analysis of depression, quality of life, and safety outcomes. Focus Am Psychiatr Publ. 2016;14(2):244–265. PubMed CrossRef
- Vieta E, Earley WR, Burgess MV, et al. Long-term safety and tolerability of cariprazine as adjunctive therapy in major depressive disorder. Int Clin Psychopharmacol. 2019;34(2):76–83. PubMed CrossRef
- Yoon S, Jeon SW, Ko Y-H, et al. Adjunctive brexpiprazole as a novel effective strategy for treating major depressive disorder: a systematic review and meta-analysis. J Clin Psychopharmacol. 2017;37(1):46–53. PubMed CrossRef
- Albert U, Carmassi C, Cosci F, et al. Role and clinical implications of atypical antipsychotics in anxiety disorders, obsessive-compulsive disorder, trauma-related, and somatic symptom disorders: a systematized review. Int Clin Psychopharmacol. 2016;31(5):249–258. PubMed CrossRef
- Pignon B, Tezenas du Montcel C, Carton L, et al. The place of antipsychotics in the therapy of anxiety disorders and obsessive-compulsive disorders. Curr Psychiatry Rep. 2017;19(12):103. PubMed CrossRef
- de Miranda AS, Ferreira RN, Teixeira AL, et al. Mood Stabilizers: Quetiapine. NeuroPsychopharmacotherapy; 2020:1–23.
- Jensen NH, Rodriguiz RM, Caron MG, et al. N-desalkylquetiapine, a potent norepinephrine reuptake inhibitor and partial 5-HT1A agonist, as a putative mediator of quetiapine’s antidepressant activity. Neuropsychopharmacology. 2008;33(10):2303–2312. PubMed CrossRef
- Duncan D, Cooke L, Symonds C, et al. Quetiapine use in adults in the community: a population-based study in Alberta, Canada. BMJ Open. 2016;6(3):e010861. PubMed CrossRef
- Ketter TA, Miller S, Dell’Osso B, et al. Treatment of bipolar disorder: Review of evidence regarding quetiapine and lithium. J Affect Disord. 2016;191:256–273. PubMed CrossRef
- Ignácio ZM, Calixto AV, da Silva RH, et al. The use of quetiapine in the treatment of major depressive disorder: evidence from clinical and experimental studies. Neurosci Biobehav Rev. 2018;86:36–50. PubMed CrossRef
- Maneeton N, Maneeton B, Woottiluk P, et al. Quetiapine monotherapy in acute treatment of generalized anxiety disorder: a systematic review and meta-analysis of randomized controlled trials. Drug Des Devel Ther. 2016;10:259–276. PubMed CrossRef
- Stein DJ, Bandelow B, Merideth C, et al. Efficacy and tolerability of extended release quetiapine fumarate (quetiapine XR) monotherapy in patients with generalised anxiety disorder: an analysis of pooled data from three 8-week placebo-controlled studies. Hum Psychopharmacol. 2011;26(8):614–628. PubMed CrossRef
- Endicott J, Svedsäter H, Locklear JC. Effects of once-daily extended release quetiapine fumarate on patient-reported outcomes in patients with generalized anxiety disorder. Neuropsychiatr Dis Treat. 2012;8:301–311. PubMed CrossRef
- Thase ME, Demyttenaere K, Earley WR, et al. Extended release quetiapine fumarate in major depressive disorder: analysis in patients with anxious depression. Depress Anxiety. 2012;29(7):574–586. PubMed CrossRef
- Bandelow B, Bauer M, Vieta E, et al. Extended release quetiapine fumarate as adjunct to antidepressant therapy in patients with major depressive disorder: pooled analyses of data in patients with anxious depression versus low levels of anxiety at baseline. World J Biol Psychiatry. 2014;15(2):155–166. PubMed CrossRef
- McIntyre A, Gendron A, McIntyre A. Quetiapine adjunct to selective serotonin reuptake inhibitors or venlafaxine in patients with major depression, comorbid anxiety, and residual depressive symptoms: a randomized, placebo-controlled pilot study. Depress Anxiety. 2007;24(7):487–494. PubMed CrossRef
- Li X, Xing B, Yu E, et al. The combined treatment of venlafaxine and quetiapine for treatment-resistant depression: a clinical study. J Neuropsychiatry Clin Neurosci. 2013;25(2):157–160. PubMed CrossRef
- Li R, Wu R, Chen J, et al. A randomized, placebo-controlled pilot study of quetiapine-XR monotherapy or adjunctive therapy to antidepressant in acute major depressive disorder with current generalized anxiety disorder. Psychopharmacol Bull. 2016;46(1):8–23. PubMed
- Chen Y-C, Chen C-K, Wang L-J. Quetiapine fumarate augmentation for patients with a primary anxiety disorder or a mood disorder: a pilot study. BMC Psychiatry. 2012;12(1):162. PubMed CrossRef
- First MB, Spitzer RL, Gibbon M, et al. Structured Clinical Interview for DSM-IV-TR Axis I Disorders: Patient Edition. Biometrics Research Department, Columbia University: New York, NY; 2005.
- Hamilton M. A rating scale for depression. J Neurol Neurosurg Psychiatry. 1960;23(1):56–62. PubMed CrossRef
- Hamilton M. The assessment of anxiety states by rating. Br J Med Psychol. 1959;32(1):50–55. PubMed CrossRef
- Guy W. ECDEU Assessment Manual for Psychopharmacology. US Department of Health, Education, and Welfare, Public Health Service; 1976.
- Montgomery SA, Åsberg M. A new depression scale designed to be sensitive to change. Br J Psychiatry. 1979;134(4):382–389. PubMed CrossRef
- Beck AT, Ward CH, Mendelson M, et al. An inventory for measuring depression. Arch Gen Psychiatry. 1961;4(6):561–571. PubMed CrossRef
- Endicott J, Nee J, Harrison W, et al. Quality of Life Enjoyment and Satisfaction Questionnaire: a new measure. Psychopharmacol Bull. 1993;29(2):321–326. PubMed
- Meyer TJ, Miller ML, Metzger RL, et al. Development and validation of the Penn State Worry Questionnaire. Behav Res Ther. 1990;28(6):487–495. PubMed CrossRef
- Liebowitz MR. Social phobia. Mod Probl Pharmacopsychiatry. 1987;22:141–173. PubMed CrossRef
- Shear MK, Brown TA, Barlow DH, et al. Multicenter collaborative panic disorder severity scale. Am J Psychiatry. 1997;154(11):1571–1575. PubMed CrossRef
- McIntyre RS, Muzina DJ, Adams A, et al. Quetiapine XR efficacy and tolerability as monotherapy and as adjunctive treatment to conventional antidepressants in the acute and maintenance treatment of major depressive disorder: a review of registration trials. Expert Opin Pharmacother. 2009;10(18):3061–3075. PubMed CrossRef
- Stein MB, Fuetsch M, Müller N, et al. Social anxiety disorder and the risk of depression: a prospective community study of adolescents and young adults. Arch Gen Psychiatry. 2001;58(3):251–256. PubMed CrossRef
- Bandelow B, Reitt M, Röver C, et al. Efficacy of treatments for anxiety disorders: a meta-analysis. Int Clin Psychopharmacol. 2015;30(4):183–192. PubMed CrossRef
- de Graaf R, Bijl RV, Ten Have M, et al. Pathways to comorbidity: the transition of pure mood, anxiety and substance use disorders into comorbid conditions in a longitudinal population-based study. J Affect Disord. 2004;82(3):461–467. PubMed CrossRef
- Khan A, Detke M, Khan SR, et al. Placebo response and antidepressant clinical trial outcome. J Nerv Ment Dis. 2003;191(4):211–218. PubMed CrossRef
- Maslej MM, Furukawa TA, Cipriani A, et al. Individual differences in response to antidepressants: a meta-analysis of placebo-controlled randomized clinical trials. JAMA Psychiatry. 2020;77(6):607–617. Retracted in: JAMA Psychiatry. 2020;77(8):786. PubMed CrossRef
- McElroy SL, Weisler RH, Chang W, et al; EMBOLDEN II (Trial D1447C00134) Investigators. A double-blind, placebo-controlled study of quetiapine and paroxetine as monotherapy in adults with bipolar depression (EMBOLDEN II). J Clin Psychiatry. 2010;71(2):163–174. PubMed CrossRef
- Young AH, McElroy SL, Bauer M, et al; EMBOLDEN I (Trial 001) Investigators. A double-blind, placebo-controlled study of quetiapine and lithium monotherapy in adults in the acute phase of bipolar depression (EMBOLDEN I). J Clin Psychiatry. 2010;71(2):150–162. PubMed CrossRef
- Thase ME, Macfadden W, Weisler RH, et al; BOLDER II Study Group. Efficacy of quetiapine monotherapy in bipolar I and II depression: a double-blind, placebo-controlled study (the BOLDER II study). J Clin Psychopharmacol. 2006;26(6):600–609. PubMed CrossRef
- Hirschfeld RM, Weisler RH, Raines SR, et al; BOLDER Study Group. Quetiapine in the treatment of anxiety in patients with bipolar I or II depression: a secondary analysis from a randomized, double-blind, placebo-controlled study. J Clin Psychiatry. 2006;67(3):355–362. PubMed CrossRef
- Thase ME. Quetiapine monotherapy for bipolar depression. Neuropsychiatr Dis Treat. 2008;4(1):11–21. PubMed CrossRef